3-(5-甲氧基-2-甲基-吲哚-3-基)-丙酸 | 39972-31-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 3-(5-甲氧基-2-甲基-吲哚-3-基)-丙酸
• 英文名称: 3-(5-methoxy-2-methyl-indol-3-yl)-propionic acid
• 英文别名: 3-(5-Methoxy-2-methylindol-3-yl)propanoic acid；3-(5-Methoxy-2-methylindolyl)propanoic acid；3-(5-methoxy-2-methyl-1H-indol-3-yl)propanoic acid
• CAS: 39972-31-1
• 化学式: C₁₃H₁₅NO₃
• 分子量: 233.267
• InChiKey: HUSQFQICATVSMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  62.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(5-甲氧基-2-甲基-吲哚-3-基)-丙酸 在 硫酸 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-methoxy-2-methyl-1-(phenylmethyl)-1H-indole-3-propanoic acid methyl ester
  参考文献：
  名称：

  Indole derivatives as potent inhibitors of 5-lipoxygenase: Design, synthesis, biological evaluation, and molecular modeling

  摘要：

  A series of novel indole derivatives was designed, synthesized and evaluated by cell-based assays for their inhibitory activities against 5-LOX in rat peritoneal leukocytes. Most of them (30 out of 35) showed an inhibitory potency higher than the initial screening hit 1a (IC50 = 74 mu M). Selected compounds for concentration-response studies showed prominent inhibitory activities with IC50 values ranging from 0.74 mu M to 3.17 mu M. Four compounds (1m, 1s, 4a, and 6a) exhibited the most potent inhibitory activity compared to that of the reference drug (Zileuton), with IC50 values less than I mu M. Molecular modeling studies for compounds 1a, 3a, 4a, and 6a were also presented. The excellent in vitro activities of this class of compounds may possess potential for the treatment of LT-related diseases. (C) 2007 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2007.02.038
• 作为产物：
  描述：

  5-氧代己酸 、 3-甲氧基苯肼盐酸 以 溶剂黄146 为溶剂， 生成 3-(5-甲氧基-2-甲基-吲哚-3-基)-丙酸
  参考文献：
  名称：

  N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase

  摘要：

  这项发明涵盖了式I的新化合物，以及一种治疗环氧合酶-2介导疾病的方法，包括向需要此类治疗的患者施用式I化合物的非毒性治疗有效量。 该发明还涵盖了用于治疗环氧合酶-2介导疾病的某些含有式I化合物的药物组合物。

  公开号：

  US05604253A1

文献信息

• Substituted indoles and their use as integrin antagonists
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20020169200A1

  公开（公告）日：2002-11-14

  The present invention relates to novel substituted indole compounds that are antagonists of alpha V (&agr;v) integrins, for example &agr; v &bgr; 3 and &agr; v &bgr; 5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by &agr; v &bgr; 3 and &agr; v &bgr; 5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: 1 where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , D, X, W, a, m, n, i, j, k and v are defined herein.

  本发明涉及新型取代吲哚化合物，其为αV（αv）整合素的拮抗剂，例如αvβ3和αvβ5整合素，其药学上可接受的盐以及其药物组合物。这些化合物可用于治疗由αvβ3和αvβ5整合素介导的病理性状况，包括肿瘤生长、转移、再狭窄、骨质疏松、炎症、黄斑变性、糖尿病视网膜病变和类风湿性关节炎等病症。这些化合物具有以下一般式： 1 其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、D、X、W、a、m、n、i、j、k和v在此处定义。
• [EN] HIGHLY ACTIVE SELF-SUFFICIENT NITRATION BIOCATALYSTS<br/>[FR] BIOCATALYSEURS DE NITRATION AUTO-SUFFISANTS HAUTEMENT ACTIFS
  申请人：UNIV FLORIDA

  公开号：WO2018081456A1

  公开（公告）日：2018-05-03

  The disclosure relates to the field of fusion proteins. In some aspects, the disclosure relates to artificial fusion proteins comprising cytochrome P450 enzymes linked to reductase enzymes and uses thereof. In some aspects, the disclosure relates to compounds produced by artificial cytochrome P450 enzymes.

  该披露涉及融合蛋白的领域。在某些方面，该披露涉及人工融合蛋白，其中包括与还原酶酶相连的细胞色素P450酶，并其用途。在某些方面，该披露涉及由人工细胞色素P450酶产生的化合物。
• [EN] SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS<br/>[FR] INDOLES SUBSTITUES ET UTILISATION DE CEUX-CI COMME ANTAGONISTES D'INTEGRINE
  申请人：DIMENSIONAL PHARM INC

  公开号：WO2002060438A1

  公开（公告）日：2002-08-08

  The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in treatment of pathological conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: (IV) where R?1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14¿, D, X, W, a, m, n, I, j, k and v are defined herein.

  本发明涉及一种新型的取代吲哚化合物，它们是αV（αv）整合素的拮抗剂，例如αvβ3和αvβ5整合素，它们的药学上可接受的盐和制药组合物。这些化合物可用于治疗由αvβ3和αvβ5整合素介导的病理状况，包括肿瘤生长、转移、再狭窄、骨质疏松、炎症、黄斑变性、糖尿病视网膜病变和类风湿性关节炎等疾病。这些化合物具有通式：（IV），其中R?1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14¿、D、X、W、a、m、n、I、j、k和v在此定义。
• Substituted Indoles and Their Use as Integrin Antagonists
  申请人：Lu Tianbo

  公开号：US20070219233A1

  公开（公告）日：2007-09-20

  The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example α v β 3 and α v β 5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by α v β 3 and α v β 5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , D, X, W, a, m, n, i, j, k and v are defined herein.

  本发明涉及一种新型的取代吲哚化合物，它们是αV（αv）整合素的拮抗剂，例如αvβ3和αvβ5整合素，它们的药学上可接受的盐和制药组合物。这些化合物可用于治疗由αvβ3和αvβ5整合素介导的病理状况，包括肿瘤生长、转移、再狭窄、骨质疏松、炎症、黄斑变性、糖尿病视网膜病变和类风湿性关节炎等疾病。该化合物具有以下通式：其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、D、X、W、a、m、n、i、j、k和v在此定义。
• Iodine(III)-Mediated C–C Bond Coupling to Construct Spirocyclic Indolenines of Various Ring Sizes
  作者：Yanren Zhu、Shaoxiong Yang、Enfan Pu、Li Li、Silei Ye、Longsheng Wei、Guolan Ma、Yushun Zhang、Hongbin Zhang、Jingbo Chen

  DOI：10.1021/acs.orglett.3c01106

  日期：2023.5.19

  iodine(III)-mediated intramolecular dearomative spirocyclization of indole derivatives to generate highly strained spirocyclobutyl, spirocyclopentyl, and spirocyclohexyl indolenines in moderate to good yields. A set of structurally novel, densely functionalized spiroindolenines with broad functional group compatibility was efficiently constructed in this way under mild reaction conditions. Moreover

  在此，我们报告了一种新型的碘 (III) 介导的吲哚衍生物的分子内脱芳环化螺环化，以中等至良好的收率生成高度应变的螺环丁基、螺环戊基和螺环己基吲哚啉。在温和的反应条件下，以这种方式有效地构建了一组具有广泛官能团相容性的结构新颖、密集官能化的螺吲哚。此外，β-烯胺酯作为产品中的多功能官能团，为生物活性化合物及相关天然产物的合成提供了极大的便利。